Updates are available Correction dated 2024-07-27
Click to view Correction: https://doi.org/10.1186/s13024-024-00744-6
-
Authors
Calliari, Anna
Daughrity, Lillian M.
Albagli, Ellen A.
Castellanos Otero, Paula
Yue, Mei
Jansen-West, Karen
Islam, Naeyma N.
Caulfield, Thomas
Rawlinson, Bailey
DeTure, Michael
Cook, Casey
Graff-Radford, Neill R.
Day, Gregory S.
Boeve, Bradley F.
Knopman, David S.
Petersen, Ronald C.
Josephs, Keith A.
Oskarsson, Björn
Gitler, Aaron D.
Dickson, Dennis W.
Gendron, Tania F.
Prudencio, Mercedes
Ward, Michael E.
Zhang, Yong-Jie
Petrucelli, Leonard http://orcid.org/0000-0003-2959-129X
-
Funding
Funding for this research was provided by:
Target ALS (Target ALS, Target ALS, Target ALS, Target ALS)
Robert Packard Center for ALS Research, Johns Hopkins University (Robert Packard Center for ALS Research, Johns Hopkins University)
National Institute on Aging (5P30AG0062677, U19AG063911, U19AG063911, U19AG063911, U19AG063911, U19AG063911, U19AG063911, R01AG37491)
National Institute of Neurological Disorders and Stroke (U54NS123743, U54NS123743, U54NS123743, R35NS097273 (17,24), R35NS097263(10,10), P01NS084974, P01NS084974, P01NS084974, P01NS084974, RF1NS120992, RF1NS120992, R01NS117461, R01NS117461, R21NS127331)
- License Information
-
More Information
Article History
Received: 9 February 2024
Accepted: 11 March 2024
First Online: 27 March 2024
Change Date: 27 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13024-024-00744-6
Declarations
:
: Human postmortem brain tissues from amygdala and frontal cortex were provided by the Mayo Clinic Florida Brain Bank. Diagnosis was independently ascertained by trained neurologists and neuropathologists upon neurological and pathological examinations, respectively. All participants, or the next of kin, provided written informed consent, and all protocols were reviewed and approved by the Mayo Clinic Institutional Review Board and Ethics Committee.
: All authors have reviewed the final manuscript and consent to publication.
: B.F.B. receives institutional research grant support from Alector, Biogen, Transposon, Cognition Therapeutics, and GE Healthcare. B.F.B. receives an honorarium for SAB activities for the Tau Consortium. L.P. is a consultant for Expansion Therapeutics. D.S.K. serves on a Data Safety Monitoring Board for the Dominantly Inherited Alzheimer Network Treatment Unit study. D.S.K. served on a Data Safety monitoring Board for a tau therapeutic for Biogen (until 2021) but received no personal compensation. D.S.K. is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the University of Southern California. D.S.K. has served as a consultant for Roche, Samus Therapeutics, Magellan Health, Biovie and Alzeca Biosciences but receives no personal compensation. D.S.K. attended an Eisai advisory board meeting for lecanemab. A.D.G. is a scientific founder of Maze Therapeutics.
